Prulifloxacin is a fluoroquinolone with broad spectrum antibacterial activity against Gram-positive and Gram-negative bacteria. Prulifloxacin is an inhibitor of Topo II.
In vivo evaluation of NM441, a new thiazeto-quinoline derivative: M. Ozaki, et al.; Antimicrob. Agents Chemother. 35, 2496 (1991) Studies on pyridonecarboxylic acids. 1. Synthesis and antibacterial evaluation of 7-substituted-6-halo-4- oxo-4H-[1,3]thiazeto[3,2-a]quinoline-3- carboxylic acids: J. Segawa, et al.; J. Med. Chem. 35, 4727 (1992) Pharmacokinetics and safety of NM441, a new quinolone, in healthy male volunteers: M. Nakashima, et al.; J. Clin. Pharmacol. 34, 930 (1994) Randomized, double-blind study of prulifloxacin versus ciprofloxacin in patients with acute exacerbations of chronic bronchitis: C. Grassi, et al.; Respiration 69, 217 (2002) Pharmacologic characteristics of prulifloxacin: M.G. Matera; Pulm. Pharmacol. Ther. 19, 20 (2006) Prulifloxacin: a new fluoroquinolone for the treatment of acute exacerbation of chronic bronchitis: M. Cazzola, et al.; Pulm. Pharmacol. Ther. 19, 30 (2006) Prulifloxacin: a new antibacterial fluoroquinolone: G. Prats, et al.; Expert. Rev. Anti. Infect. Ther. 4, 27 (2006), (Review)
Santa Cruz Biotechnology, Inc. is a world leader in the development of products for the biomedical research market. Call us Toll Free at 1-800-457-3801.
Copyright © 2007-2019 Santa Cruz Biotechnology, Inc. All Rights Reserved. "Santa Cruz Biotechnology", and the Santa Cruz Biotechnology, Inc. logo, "Santa Cruz Animal Health", "San Juan Ranch", "Supplement of Champions", the San Juan Ranch logo, "Ultracruz", "Chemcruz", "Immunocruz", "Exactacruz", and "EZ Touch" are registered trademarks of Santa Cruz Biotechnology, Inc.
All trademarks are the property of their respective owners.